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Key	points	summary	23	
- Heart	rate	is	increased	in	chronic	hypoxia	and	we	tested	whether	this	is	the	result	24	
of	increased	sympathetic	nervous	activity,	reduced	parasympathetic	nervous	25	
activity,	or	a	non-autonomic	mechanism.	26	
- In	seven	lowlanders,	heart	rate	was	measured	at	sea	level	and	after	two	weeks	at	27	
high	altitude	after	individual	and	combined	pharmacological	inhibition	of	28	
sympathetic	and/or	parasympathetic	control	of	the	heart.	29	
- Inhibition	of	parasympathetic	control	of	the	heart	alone	or	in	combination	with	30	
inhibition	of	sympathetic	control	abolished	the	high	altitude-induced	increase	in	31	
heart	rate.	32	
- Inhibition	of	sympathetic	control	of	the	heart	alone	did	not	prevent	the	high	33	
altitude-induced	increase	in	heart	rate.	34	
- These	results	indicate	that	a	reduced	parasympathetic	nervous	activity	is	the	main	35	
mechanism	underlying	the	elevated	heart	rate	in	chronic	hypoxia.	36	
	37	
	 	38	
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Abstract	39	
Chronic	hypoxia	increases	resting	heart	rate	(HR),	but	the	underlying	mechanism	remains	40	
incompletely	understood.	We	investigated	the	relative	contributions	of	the	sympathetic	41	
and	parasympathetic	nervous	systems,	along	with	potential	non-autonomic	mechanisms,	42	
by	individual	and	combined	pharmacological	inhibition	of	muscarinic	and/or	β-adrenergic	43	
receptors.	44	
In	seven	healthy	lowlanders,	resting	HR	was	determined	at	sea	level	(SL)	and	after	15-18	45	
days	of	exposure	to	3,454	m	high	altitude	(HA)	without	drug	intervention	(CONT)	as	well	46	
as	after	intravenous	administration	of	either	propranolol	(PROP),	glycopyrrolate	(GLYC),	or	47	
PROP	and	GLYC	in	combination	(PROP+GLYC).	48	
Circulating	norepinephrine	concentration	increased	from	0.9±0.4	nmol-1	at	SL	to	2.7±1.5	49	
nmol-1	at	HA	(p=0.03).	The	effect	of	HA	on	HR	depended	on	the	type	of	autonomic	50	
inhibition	(p=0.006).	Specifically,	HR	was	increased	at	HA	from	64±10	to	74±12	beats	min-1	51	
during	CONT	(p=0.007)	and	from	52±4	to	59±5	beats	min-1	during	PROP	(p<0.001).	In	52	
contrast,	HR	was	similar	between	SL	and	HA	during	GLYC	(110±7	and	112±5	beats	min-1,	53	
p=0.28)	and	PROP+GLYC	(83±5	and	85±5	beats	min-1,	p=0.25).	54	
Our	results	identify	a	reduction	in	cardiac	parasympathetic	activity	as	the	primary	55	
mechanism	underlying	the	elevated	HR	associated	with	two	weeks	of	exposure	to	56	
hypoxia.	Unexpectedly,	the	sympathoactivation	at	HA	that	was	evidenced	by	increased	57	
circulating	norepinephrine	concentration	had	little	effect	on	HR,	potentially	reflecting	58	
down-regulation	of	cardiac	β-adrenergic	receptor	function	in	chronic	hypoxia.	These	59	
effects	of	chronic	hypoxia	on	autonomic	control	of	the	heart	may	concern	not	only	HA	60	
dwellers,	but	also	patients	with	disorders	that	are	associated	with	hypoxemia.	61	
	 	62	
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Abbreviations	63	
CaO2,	arterial	oxygen	content;	CONT,	control;	GLYC,	glycopyrrolate;	HA,	high	altitude;	HR,	64	
heart	rate;	PROP,	propranolol;	PROP+GLYC,	propranolol	and	glycopyrrolate	in	65	
combination;	SL,	sea	level	66	
	 	67	
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Introduction	68	
	69	
Acute	exposure	to	hypoxia	accelerates	resting	heart	rate	(HR)	by	facilitating	70	
sympathoactivation	and	parasympathetic	withdrawal	(Koller	et	al.,	1988;	Siebenmann	et	71	
al.,	2015b).	As	hypoxic	exposure	extends,	HR	remains	elevated	despite	the	progressive	72	
restoration	of	arterial	O2	content	(CaO2)	that	occurs	with	acclimatization	(Wolfel	et	al.,	73	
1994;	Hansen	&	Sander,	2003;	Naeije,	2010).	The	persistent	activation	of	the	sympathetic	74	
nervous	system	that	accompanies	chronic	hypoxia	(Hansen	&	Sander,	2003)	may	seem	an	75	
obvious	explanation	for	the	elevated	HR.	Nevertheless,	pharmacological	inhibition	of	β-76	
adrenergic	receptors	did	not	abolish	the	increase	in	HR	associated	with	two	weeks	of	77	
exposure	to	high	altitude	(HA)	(Hughson	et	al.,	1994;	Wolfel	et	al.,	1994),	implying	a	78	
contribution	of	sustained	parasympathetic	withdrawal.	Surprisingly,	however,	79	
administration	of	muscarinic	receptor	antagonists	induced	a	more	pronounced	increase	in	80	
HR	after	9	weeks	at	HA	than	at	sea	level	(SL),	indicating	increased	parasympathetic	activity	81	
(Boushel	et	al.,	2001).	These	conflicting	observations	could	relate	to	methodological	82	
differences,	most	notably	the	inhibition	of	different	receptor	types,	as	well	as	different	83	
subject	groups	and	HA	exposure	protocols.	The	interpretation	is	further	complicated	since	84	
all	these	studies	inhibited	only	one	receptor	type,	requiring	divergent	analytical	85	
approaches	to	assess	the	respective	contributions	of	the	sympathetic	and	86	
parasympathetic	nervous	system	to	the	increased	HR.	Another	explanation	could	be	that	87	
an	unknown,	non-autonomic	mechanism	contributes	to	the	increased	HR	in	chronic	88	
hypoxia.	Such	changes	of	intrinsic	heart	rate	could	be	demonstrated	during	simultaneous	89	
inhibition	of	β-adrenergic	and	muscarinic	receptors,	which	has	to	our	knowledge	never	90	
been	conducted	in	chronic	hypoxia.	91	
The	aim	of	this	study	was	to	advance	our	understanding	of	the	regulation	of	the	increased	92	
HR	in	chronic	hypoxia	by	isolating	the	relative	contributions	of	the	sympathetic	and	93	
parasympathetic	nervous	systems	as	well	as	of	potential	non-autonomic	mechanisms.	In	94	
seven	lowlanders	exposed	for	15-18	days	to	HA,	we	compared	HR	between	SL	and	HA	95	
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after	pharmacological	inhibition	of	either	muscarinic	or	β-adrenergic	receptors,	or	both	96	
receptor	types	in	combination.	Based	on	findings	in	acute	hypoxia	(Siebenmann	et	al.,	97	
2015b),	we	hypothesized	that	both	sympathoactivation	and	parasympathetic	withdrawal	98	
contribute	to	the	increased	HR	in	chronic	hypoxia,	so	that	individual	inhibition	of	either	99	
receptor	type	would	not	prevent	the	acceleration	of	HR	at	HA.	We	further	hypothesized	100	
that	full	cardiac	autonomic	blockade	would	abolish	the	HA-induced	increase	in	HR	and	101	
hence	exclude	a	contribution	of	a	non-autonomic	mechanism.	102	
	 	103	
7	
	
Methods	104	
	105	
Ethical	approval	106	
This	study	was	approved	by	the	ethical	committee	of	the	Swiss	Federal	Institute	of	107	
Technology	(EK	2011-N-51)	and	conducted	in	accordance	with	the	current	version	of	the	108	
declaration	of	Helsinki.	All	subjects	gave	written	and	oral	consent	to	participation.	109	
	110	
Participants	111	
Seven	healthy,	male,	Caucasian	lowlanders	(26	±	4	yrs;	180	±	1	cm;	76	±	6	kg)	were	112	
recruited	as	study	subjects.	All	were	physically	active	on	a	recreational	basis.	Subjects	113	
refrained	from	travelling	to	altitudes	>	2,000	m	within	the	last	four	weeks	before	the	114	
experiments.	115	
	116	
Protocol	117	
This	study	took	place	at	the	University	of	Zürich,	Switzerland	(460	m,	referred	to	as	SL)	and	118	
during	a	four-week	sojourn	at	the	Jungfraujoch	research	station	in	the	Swiss	Alps	(3,454	119	
m,	referred	to	as	HA).	This	station	offers	private	bedrooms	for	all	subjects,	kitchen	120	
facilities	and	living	space,	all	with	normal	room	temperatures.	Subjects	were	transported	121	
to	HA	and	back	to	SL	by	train.	During	the	HA	sojourn,	they	preserved	physical	activity	by	122	
hiking,	mountaineering	and	ergometer	cycling.	Drinking	water	was	always	available	ad	123	
libitum	and	subjects	were	instructed	to	maintain	their	habitual	diets,	for	which	they	124	
ordered	the	required	groceries.	As	previously	reported,	both	body	weight	and	125	
composition	were	maintained	throughout	the	HA	sojourn	(Jacobs	et	al.,	2012).	126	
Experiments	were	scheduled	during	the	last	week	before	ascent	and	then	after	15-18	days	127	
at	HA.	At	both	altitudes,	the	experiments	followed	the	same	protocol	and	were	conducted	128	
at	normal	room	temperature,	by	the	same	investigators,	and	using	the	same	equipment:	129	
Participants	reported	to	the	laboratory	on	two	days,	separated	by	2	–	4	days.	On	both	130	
days,	a	venous	catheter	was	inserted	into	an	antecubital	vein.	An	additional	catheter	was	131	
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inserted	under	local	anaesthesia	into	a	radial	artery	on	the	second	day	only.	After	132	
catheterization,	subjects	were	placed	in	a	semi-recumbent	position.	On	the	second	day,	2	133	
ml	of	arterial	blood	were	collected	and	analysed	in	a	haemoximeter	(ABL	800,	Radiometer,	134	
Copenhagen,	Denmark).	Subjects	then	remained	still	for	~	10	min,	while	arterial	pressure	135	
was	continuously	monitored	on	the	finger	by	the	volume	clamp	method	(Finometer	PRO,	136	
Finapres	Medical	Systems	B.V.,	Amsterdam,	Netherlands).	HR	was	derived	as	the	inverse	137	
of	the	inter-beat	interval.	Cardiac	stroke	volume	was	determined	from	the	blood	pressure	138	
waveform	by	a	three-element	model	of	arterial	input	impedance	(Modelflow)	139	
incorporating	age,	sex,	height,	and	weight	(Wesseling	et	al.,	1993).	Cardiac	output	was	140	
calculated	as	HR	×	stroke	volume.	Data	was	recorded	at	a	frequency	of	1	kHz	(Powerlab,	141	
ADInstruments,	Bella	Vista,	Australia).	For	the	analysis	we	used	the	120	successive	heart	142	
beats	with	the	lowest	variation.	143	
On	the	first	day,	measurements	were	conducted	without	receptor	inhibition	(CONT),	and	144	
then	after	administration	of	GLYC.	On	the	second	day,	measurements	were	performed	145	
after	administration	of	PROP,	and	then	after	additional	administration	of	GLYC	146	
(PROP+GLYC).	Neither	the	investigators	nor	the	subjects	were	blinded	towards	the	drug	147	
condition.	148	
	149	
Drug	administration	150	
GLYC	was	infused	for	5	minutes	at	a	rate	of	2.5	µg	kg-1	min-1.	Subsequently,	an	additional	151	
bolus	of	50	µg	was	injected	every	2	min	until	the	HR	response	to	the	bolus	was	<	10	%.	152	
Receptor	inhibition	was	thereafter	maintained	by	continuous	infusion	of	0.05	µg	kg-1	min-1	153	
until	termination	of	the	measurements.	PROP	was	infused	at	a	rate	of	15	µg	kg-1	min-1	for	154	
15	min.	β-receptor	inhibition	was	subsequently	challenged	by	infusion	of	a	60	µg	bolus	of	155	
isoprenaline	and	an	additional	1	mg	bolus	of	PROP	was	injected	every	2	min	until	the	HR	156	
response	to	isoprenaline	was	<	10	%.	A	continuous	administration	of	0.8	µg	kg-1	min-1	was	157	
thereafter	maintained	throughout	the	measurements.	After	completion	of	the	PROP	158	
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experiments,	GLYC	was	administered	according	to	the	protocol	specified	above,	while	159	
sustaining	the	continuous	infusion	of	PROP.	160	
All	drugs	were	administered	by	means	of	an	automated	infusion	pump	(Harvard	161	
Apparatus,	Harvard	Biosciences,	Cambridge,	UK).	During	GLYC,	the	final	dose	was	4.3	±	0.5	162	
mg	at	SL	and	3.9	±	0.3	mg	at	HA.	During	PROP,	the	final	dose	was	21.7	±	1.6	mg	at	SL	and	163	
21.0	±	1.9	mg	at	HA.	During	PROP+GLYC,	the	final	doses	of	the	two	drugs	were	26.7	±	1.8	164	
(including	the	dose	applied	in	the	preceding	PROP	experiment)	and	4.6	±	0.3	mg	at	SL	and	165	
25.6	±	2.6	and	3.7	±	0.7	mg	at	HA.	166	
	167	
Venous	norepinephrine	168	
At	SL	as	well	as	after	2,	10	and	26	days	at	HA,	5	ml	of	venous	blood	were	collected.	Blood	169	
compartments	were	separated	by	centrifugation	and	the	plasma	immediately	frozen	in	170	
liquid	nitrogen	and	stored	at	-80°	C.	Venous	norepinephrine	was	measured	in	these	171	
samples	as	a	marker	for	sympathetic	activity	by	liquid	chromatography-mass	172	
spectrometry.	173	
	174	
Blood	withdrawal	for	other	experiments	175	
Over	the	course	of	the	five	weeks	preceding	ascent	to	HA	a	total	of	~150	ml	of	whole	176	
blood	was	withdrawn	for	different	study	purposes.	At	HA,	at	total	of	~120	ml	of	blood	was	177	
withdrawn	at	various	time	points	before	the	experiments	reported	here	were	conducted.	178	
	179	
Statistics	180	
To	assess	the	effect	of	HA	within	the	different	drug	conditions	we	used	a	mixed	model	for	181	
repeated	measures	approach,	unless	otherwise	noted.	Level	of	subject	entered	as	a	182	
random	effect	while	drug	and	altitude	levels	entered	as	fixed	effects.	For	changes	in	183	
venous	norepinephrine	concentration	time	from	start	of	HA	sojourn	entered	as	fixed	184	
effect.	Where	applicable,	Tukey’s	post-hoc	test	was	used	for	pairwise	comparison.	HA-185	
induced	changes	in	indices	of	arterial	oxygenation	were	assessed	by	student’s	t-test	and	186	
10	
	
SAS	Enterprise	Guide	6	(SAS	Institute	Inc.,	Cary,	NC,	USA)	was	used	for	the	analysis.	A	p-187	
value	<	0.05	was	considered	significant	and	values	represent	means	±	S.D.	188	
	 	189	
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Results	190	
	191	
Arterial	blood	analysis	(Table	1)	192	
Arterial	O2	tension	and	oxyhaemoglobin	saturation	were	reduced	at	HA	(p	<	0.001).	This	193	
was,	however,	compensated	by	an	increase	in	haematocrit	(p	=	0.008)	and	haemoglobin	194	
concentration	(p	=	0.002),	so	that	CaO2	was	higher	at	HA	than	at	SL	(p	=	0.04).	195	
	196	
Heart	rate	(Fig.	1)	197	
During	CONT,	HR	was	9.7	±	7.9	beats	min-1	higher	at	HA	than	at	SL	(p	=	0.007).	This	effect	198	
of	HA	was	affected	by	the	autonomic	antagonists	(p	=	0.006).	Specifically,	while	HR	was	199	
increased	at	HA	by	7.6	±	4.0	beats	min-1	during	PROP	(p	<	0.001),	it	was	only	insignificantly	200	
higher	than	at	SL	during	GLYC	(2.3	±	6.0	beats	min-1,	p	=	0.28)	and	PROP+GLYC	(2.3	±	5.4	201	
beats	min-1,	p	=	0.25).	202	
	203	
Haemodynamics	(Fig.	2)	204	
The	effect	of	HA	on	cardiac	stroke	volume	also	depended	on	the	type	of	receptor	205	
inhibition	(p	=	0.04).	While	cardiac	stroke	volume	was	only	insignificantly	lower	at	HA	than	206	
at	SL	during	CONT	(-0.2	ml	±	19.2	ml,	p	=	0.8),	a	reduction	was	observed	at	HA	during	207	
PROP	(-23.0	±	13.4	ml,	p	<	0.001),	GLYC	(-12.8	±	11.9	ml,	p	=	0.01)	and	PROP+GLYC	(-25.7	±	208	
16.1	ml,	p	<	0.001).	Similarly,	the	effect	of	HA	on	cardiac	output	tended	to	depend	on	the	209	
drug	condition	(p	=	0.06).	While	HA	numerically	increased	cardiac	output	during	CONT	by	210	
1.1	±	2.2	l	min-1	(p	=	0.2),	it	reduced	cardiac	output	during	PROP	by	0.8	±	0.8	l	min-1	(p	=	211	
0.02),	during	GLYC	by	1.1	±	1.1	l	min-1	(p	=	0.02)	and	during	PROP+GLYC	by	2.0	±	1.5	l	min-1	212	
(p	=	0.002).	213	
Mean	arterial	pressure	was	increased	at	HA	(p	=	0.001)	and	this	response	was	not	affected	214	
by	the	autonomic	antagonists	(p	=	0.9).	The	respective	increases	during	CONT,	PROP,	215	
GLYC,	and	PROP+GLYC	were	9.4	±	17.9,	10.3	±	15.3,	16.3	±	17.6	and	16.4	±	16.2	mmHg,	216	
respectively.	217	
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	218	
Venous	norepinephrine	219	
Venous	norepinephrine	concentration	was	0.9	±	0.4	nmol-1	at	SL	and	similar	(1.1	±	0.5	220	
nmol	l-1,	p	=	0.7)	on	the	second	day	at	HA.	Subsequently,	norepinephrine	concentration	221	
increased	to	2.7	±	1.5	nmol	l-1	(p	=	0.03)	on	day	10	and	to	3.0	±	1.2	nmol	l-1	(p	=	0.007)	on	222	
day	26	at	HA.	223	
	 	224	
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Discussion	225	
	226	
As	expected,	HR	during	CONT	was	higher	at	HA	than	at	SL	despite	complete	restoration	of	227	
CaO2.	A	similar	HA-induced	increase	in	HR	was	observed	when	β-adrenergic,	but	not	when	228	
muscarinic	receptors	were	inhibited.	These	results	suggest	that	cardiac	parasympathetic	229	
withdrawal	persists	throughout	HA	acclimatization	and	constitutes	the	dominating	230	
cardioacceleratory	mechanism.	The	absence	of	a	HA-induced	increase	in	HR	during	231	
combined	inhibition	of	β-adrenergic	and	muscarinic	receptors	rules	out	a	relevant	232	
contribution	of	a	non-autonomic	mechanism.	233	
	234	
Acceleration	of	resting	HR	occurs	within	the	first	seconds	of	hypoxic	exposure.	This	acute	235	
response	is	governed	by	a	combination	of	sympathoactivation	and	parasympathetic	236	
withdrawal,	although	the	respective	contributions	are	unclear	(Siebenmann	et	al.,	2015b).	237	
As	hypoxic	exposure	extends,	sympathoactivation	persists	or	increases	further	(Hansen	&	238	
Sander,	2003),	as	illustrated	in	the	present	study	by	circulating	noradrenaline.	Surprisingly,	239	
the	similar	HR	between	SL	and	HA	during	GLYC	reveals	that	the	contribution	of	this	240	
sustained	sympathoactivation	to	the	accelerated	HR	in	chronic	hypoxia	is	minor.	A	241	
potential	explanation	could	be	that	the	chronically	elevated	sympathetic	activity	facilitates	242	
a	down-regulation	of	cardiac	β-adrenergic	receptor	function	and/or	density.	This	is	243	
supported	by	the	blunted	tachycardic	response	of	humans	to	isoproterenol	infusion	after	244	
acclimatization	to	HA	(Richalet	et	al.,	1988).		245	
The	effect	of	chronic	hypoxia	on	parasympathetic	activity	is	poorly	understood,	since	246	
direct	measurement	techniques	are	not	available	in	humans.	Circulating	acetylcholine	247	
concentration	may	seem	as	an	obvious	marker	for	parasympathetic	activity,	but	248	
experimental	evidence	does	not	support	this	(Fujii	et	al.,	1997).	Instead,	spectral	analysis	249	
of	HR	variability	has	been	used	and	suggested	that	parasympathetic	withdrawal	persists	250	
even	after	18	months	at	HA	(Dhar	et	al.,	2014).	However,	this	finding	should	be	251	
interpreted	with	caution,	since	parasympathetic	indices	of	HR	variability	may	be	252	
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influenced	at	HA	by	the	concomitantly	increased	sympathetic	activity	and/or	pulmonary	253	
ventilation	(Chapleau	&	Sabharwal,	2011).	Nevertheless,	the	inability	of	PROP	to	prevent	254	
the	HA-induced	increase	in	HR	in	the	present	and	in	earlier	studies	(Hughson	et	al.,	1994;	255	
Wolfel	et	al.,	1994)	supports	persistent	parasympathetic	withdrawal	in	chronic	hypoxia.	In	256	
acute	hypoxia,	parasympathetic	withdrawal	likely	occurs	as	a	reflex	response	to	the	257	
activation	of	pulmonary	stretch	receptors	by	enhanced	ventilation	(Kato	et	al.,	1988).	258	
Ventilatory	acclimatization	facilitates	further	increases	in	pulmonary	ventilation	in	chronic	259	
hypoxia	(Bender	et	al.,	1989),	which	may	explain	persisting	parasympathetic	withdrawal.	260	
While	the	present	results	support	attenuated	parasympathetic	activity	in	chronic	hypoxia,	261	
Boushel	et	al.	(2001)	observed	that	muscarinic	inhibition	induced	a	larger	increase	in	HR	262	
after	9	weeks	at	5,300	m	than	at	SL,	and	accordingly	concluded	that	parasympathetic	tone	263	
is	increased	in	chronic	hypoxia.	Since	parasympathetic	modulation	of	HR	was	assessed	264	
without	β-adrenergic	inhibition,	this	conclusion	is	based	on	the	assumption	that	the	effect	265	
of	a	given	parasympathetic	tone	on	HR	was	not	affected	by	the	severe	sympathoactivation	266	
that	was	observed	at	HA	in	these	subjects	(Hansen	&	Sander,	2003).	Another	obvious	267	
difference	to	the	present	study	is	the	longer	exposure	to	more	severe	HA.	The	restored	268	
CaO2	in	our	subjects	indicates	that	the	most	functionally	important	acclimatization	269	
processes	were	completed	when	the	experiments	at	HA	were	conducted.	Accordingly,	it	270	
appears	unlikely	that	parasympathetic	withdrawal	would	have	reversed	to	271	
parasympathetic	activation	at	a	later	point	of	exposure.	Nevertheless,	the	longer	and	272	
more	severe	hypoxia	in	the	study	of	Boushel	et	al.	(2001)	may	have	increased	the	density	273	
of	cardiac	muscarinic	receptors	and	hence	the	bradycardic	effect	evoked	by	a	given	274	
parasympathetic	outflow	(Kacimi	et	al.,	1993).	Another	explanation	could	be	that	the	large	275	
increase	in	arterial	pressure	that	was	observed	in	that	study	(Calbet,	2003)	enhanced	276	
parasympathetic	tone	by	activation	of	arterial	baroreceptors.	In	the	present	study,	the	HA-277	
induced	increase	in	arterial	pressure	was	milder,	presumably	due	to	the	lower	altitude.	278	
In	another	study,	a	larger	HR	response	to	GLYC	administration	than	at	SL	was	observed	279	
after	the	same	duration	of	HA	exposure	as	in	the	present	study	(Bao	et	al.,	2002).	280	
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Unexpectedly,	HR	in	the	absence	of	receptor	inhibition	was	not	higher	at	HA	than	at	SL	in	281	
that	study,	which	may	explain	the	more	pronounced	difference	to	HR	measured	at	HA	282	
after	muscarinic	inhibition.	Notably,	this	study	also	applied	PROP,	which	did	not	prevent	283	
the	tachycardic	effect	of	HA.	This	is	in	agreement	with	the	present	results	and	provides	284	
evidence	that	cardiac	parasympathetic	activity	was	not	elevated	at	HA.	285	
	286	
In	order	to	examine	whether	chronic	hypoxia	increases	HR	by	a	non-autonomic	287	
mechanism	we	performed	simultaneous	inhibition	of	β-adrenergic	and	muscarinic	288	
receptors.	Such	full	autonomic	inhibition	has	previously	ruled	out	a	contribution	of	a	non-289	
autonomic	mechanism	to	the	increased	resting	HR	in	acute	hypoxia	(Siebenmann	et	al.,	290	
2015b).	Nevertheless,	functional	and	structural	cardiac	remodelling	occurs	in	lowlanders	291	
after	only	10	days	at	HA	(Stembridge	et	al.,	2014)	and	it	was	unclear	whether	this	292	
encompasses	an	increase	in	the	intrinsic	depolarization	rate	of	cardiac	pacemaker	cells.	293	
Furthermore,	chronic	hypoxia-induced	changes	in	arterial	pH	and/or	electrolyte	294	
concentration	(Severi	et	al.,	2002)	or	simply	an	unknown	mechanism	could	have	increased	295	
intrinsic	HR	independent	of	structural	changes.	The	observation	that	HR	was	similar	at	SL	296	
and	HA	during	PROP+GLYC,	however,	suggests	that	a	non-autonomic	mechanism	does	not	297	
increase	HR	in	chronic	hypoxia.	298	
	299	
We	unexpectedly	observed	that	cardiac	stroke	volume	was	not	reduced	at	HA	during	300	
CONT.	A	decrease	in	stroke	volume	usually	occurs	within	the	first	week	and	thereafter	301	
persists	throughout	HA	exposure,	likely	due	to	a	reduction	in	plasma	volume	(Siebenmann	302	
et	al.,	2013).	Since	stroke	volume	decreased	at	HA	in	all	other	drug	conditions	and	also	303	
without	drugs	at	a	later	point	of	the	HA	sojourn	(Siebenmann	et	al.,	2013),	the	absence	of	304	
a	decrease	during	CONT	presumably	reflects	a	type	2	error.	Interestingly,	the	reduction	in	305	
stroke	volume	at	HA	during	GLYC	and	PROP+GLYC,	where	HR	did	not	increase,	confirms	306	
that	a	reduced	diastolic	filling	time	is	not	a	major	component	of	the	HA-induced	reduction	307	
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in	stroke	volume	(Siebenmann	&	Lundby,	2015).	308	
	309	
There	are	several	methodological	aspects	to	consider:	First,	it	needs	to	be	appraised	310	
whether	autonomic	regulation	of	HR	after	two	weeks	of	HA	exposure	is	representative	for	311	
chronic	hypoxia.	In	support,	circulating	norepinephrine	in	the	present	and	a	previous	312	
study	(Mazzeo	et	al.,	1994)	indicate	that	sympathoactivation	reaches	a	plateau	within	the	313	
first	two	weeks	at	HA.	Furthermore,	the	limited	insight	derived	from	spectral	analysis	of	314	
HR	variability	supports	that	the	observed	withdrawal	of	parasympathetic	activity	is	at	least	315	
qualitatively	representative	for	chronic	hypoxia	(Dhar	et	al.,	2014).	Whether	potential	316	
changes	in	autonomic	receptor	function	and/or	density	affect	autonomic	regulation	of	HR	317	
at	a	later	point	of	hypoxic	exposure,	however,	remains	to	be	determined.	Second,	it	needs	318	
to	be	considered	whether	experimental	blood	withdrawal	affected	our	study	outcome.	As	319	
reported	previously	(Siebenmann	et	al.,	2013),	red	cell	volume	at	the	time	point	of	the	HA	320	
experiments	was	similar	to	SL,	suggesting	that	the	blood	withdrawal	prevented	the	~	2.5	%	321	
expansion	in	red	cell	volume	that	would	have	been	expected	at	that	point	(Siebenmann	et	322	
al.,	2015a).	Nevertheless,	the	contribution	of	red	cell	volume	expansion	to	the	restoration	323	
of	CaO2	at	this	altitude	is	small	compared	to	those	of	plasma	volume	reductions	and	324	
increases	in	arterial	O2	saturation	(Siebenmann	et	al.,	2015a).	This	is	illustrated	in	the	325	
present	study	by	the	observation	that,	despite	the	blood	withdrawal,	CaO2	was	higher	at	326	
HA	than	at	SL.	It	therefore	seems	unlikely	that	the	experimental	blood	withdrawal	exerted	327	
a	confounding	effect.	A	third	methodological	aspect	to	consider	concerns	the	use	of	PROP	328	
and	GLYC.	PROP	is	not	only	a	β-adrenergic	antagonist	but	also	possesses	membrane-329	
stabilizing	capabilities,	which	may	contribute	to	its	bradycardic	effect	(Boucher	et	al.,	330	
1992).	Nevertheless,	since	the	applied	doses	of	PROP	were	similar	between	SL	and	HA,	331	
this	membrane	stabilizing	effect	was	presumably	also	similar	and	is	hence	unlikely	to	have	332	
contributed	to	the	increased	HR	at	HA	during	PROP.	GLYC,	on	the	other	hand,	is	a	non-333	
selective	muscarinic	antagonist.	Isolation	of	sympathetic	control	of	HR	requires	that	all	334	
effects	of	parasympathetic	modulation	are	prevented.	Since	different	muscarinic	receptor	335	
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types	occur	in	the	human	heart	(Olshansky	et	al.,	2008),	a	non-specific	muscarinic	336	
antagonist	seems	appropriate	for	this	purpose.	More	specific	studies	could	now	be	337	
conducted	to	evaluate	the	roles	of	the	different	muscarinic	receptor	types	in	the	HR	338	
response	to	HA.	It	further	needs	to	be	considered	whether	PROP	and	GLYC	completely	339	
inhibited	β-adrenergic	and	muscarinic	receptors,	respectively.	Adequate	dosing	of	PROP	340	
was	confirmed	by	isoproterenol	challenge,	and	the	final	doses	conformed	to	those	that	341	
evoked	complete	cardiac	β-adrenergic	inhibition	in	dogs	(Jose	&	Taylor,	1969).	Although	342	
muscarinic	inhibition	could	not	be	challenged	by	an	agonist,	GLYC	was	applied	until	343	
additional	administration	did	not	evoke	a	further	tachycardic	response	and	the	final	doses	344	
highly	exceeded	those	used	in	related	studies	(Boushel	et	al.,	2001;	Bao	et	al.,	2002).	345	
Finally,	the	absence	of	an	effect	of	HA	on	HR	during	PROP+GLYC	supports	that	inhibition	of	346	
the	two	receptor	types	was	adequate.	Nevertheless,	during	both	GLYC	and	PROP+GLYC	347	
two	subjects	still	presented	with	a	notable	increase	in	HR	at	HA	(Fig.	1)	and	in	one	case,	348	
this	was	the	same	subject.	The	reason	for	this	persisting	increase	is	unclear	since	these	349	
subjects	had	received	similar	doses	of	GLYC	as	the	other	subjects.	Furthermore,	circulating	350	
norepinephrine	concentration	does	not	suggest	a	more	pronounced	HA-induced	351	
sympathoactivation.	It	could	be	speculated	that	cardiac	β-adrenergic	receptor	down-352	
regulation	in	chronic	hypoxia	(Richalet	et	al.,	1988)	is	subject	to	intra-individual	variability	353	
so	that	a	tachycardic	effect	of	the	increased	sympathetic	activity	at	HA	was	preserved	in	354	
some	subjects.	355	
	356	
A	limitation	of	this	study	is	the	small	number	of	subjects	included;	we	cannot	rule	out	that	357	
the	slight	numerical	increases	in	HR	at	HA	during	GLYC	and	PROP+GLYC	would	have	358	
reached	statistical	significance	in	a	larger	subject	cohort.	Nevertheless,	since	the	slight	HR	359	
increases	at	HA	during	GLYC	and	PROP+GLYC	were	considerably	smaller	than	those	360	
observed	during	CONT	and	PROP,	they	do	not	contradict	a	dominating	role	of	361	
parasympathetic	withdrawal.	A	further	limitation	is	that	our	study	was	not	double-362	
blinded.	Subject	blinding	was,	however,	not	possible	due	to	the	obvious	side	effects	of	363	
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GLYC	(dry	mouth,	difficulty	to	urinate).	Nevertheless,	HR	in	a	similar	study	proved	364	
insensitive	to	a	placebo	effect	(Wolfel	et	al.,	1994).	Furthermore,	the	120	heart	beats	365	
included	into	the	analysis	were	selected	by	our	statistics	software	and	not	by	a	researcher.	366	
Accordingly,	we	are	confident	that	blinding	of	either	subjects	or	researchers	would	not	367	
have	changed	the	study	outcome.	368	
	369	
In	conclusion,	our	results	suggest	that	parasympathetic	withdrawal	persists	and	370	
represents	the	main	mechanism	by	which	resting	HR	is	increased	in	chronic	hypoxia,	371	
whereas	the	sustained	sympathoactivation	does	not	play	a	major	role.	Furthermore,	our	372	
results	do	not	support	a	contribution	of	a	non-autonomic	mechanism.	Future	studies	373	
could	investigate	whether	changes	in	cardiac	muscarinic	receptor	density	or	function	374	
affect	the	parasympathetic	regulation	of	HR	during	longer	hypoxic	exposure.	 	375	
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Tables	476	
Table	1:	Arterial	oxygenation,	haematocrit	and	haemoglobin	concentration	at	sea	level	477	
and	at	3,454	m	altitude	478	
	 Sea	level	 High	altitude	 P-value	
PaO2	(mmHg)	 91.8	±	4.2	 63.0	±	1.5	 <	0.001	
SaO2	(%)	 96.	0	±	0.4	 89.7	±	0.7	 <	0.001	
CaO2	(ml	l-1)	 180	±	14	 185	±	14	 0.036	
Haematocrit	(%)	 42.9	±	2.6	 45.3	±	3.2	 0.008	
[Hb]	(g	l-1)	 14.0	±	1.0	 15.4	±	1.3		 <	0.001	
PaO2,	O2	tension	in	arterial	blood;	SaO2,	arterial	oxyhaemoglobin	saturation;	CaO2,	arterial	479	
O2	content;	[Hb],	haemoglobin	concentration	in	arterial	blood.	480	
	 	481	
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Figure	legends	and	figures	482	
	483	
Figure	1.	Effect	of	high	altitude	exposure	on	resting	heart	rate	484	
Points	represent	individual	values	and	the	short	horizontal	lines	the	averages	at	SL	and	485	
HA,	respectively.	P-values	are	given	for	the	comparison	between	SL	and	HA	within	the	486	
respective	drug	condition.	SL,	sea	level;	HA,	high	altitude;	CONT,	control;	PROP,	487	
propranolol;	GLYC,	glycopyrrolate;	PROP+GLYC,	propranolol	and	glycopyrrolate	in	488	
combination.	489	
	490	
Figure	2.	Effect	of	high	altitude	exposure	on	haemodynamics	491	
Data	points	represent	means	±	S.D.	*p	<	0.05	HA	vs.	SL	within	the	same	drug	condition.	SL,	492	
sea	level;	HA,	high	altitude;	CONT,	control;	PROP,	propranolol;	GLYC,	glycopyrrolate;	493	
PROP+GLYC,	propranolol	and	glycopyrrolate	in	combination.	494	
	 	495	
25	
	
	496	
	497	
Figure	1.	498	
26	
	
	499	
Figure	2.	500	
